利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN108531484B 抑制长链非编码RNA TRALR制剂的应用 失效 - 权利终止

抑制长链非编码RNA TRALR制剂的应用
摘要：
本发明公开了一种抑制长链非编码RNA TRALR制剂的应用。通过研究利用lncRNA测序发现，lncRNA TRALR在替莫唑胺抵抗的脑胶质瘤细胞系中呈异常高表达，特异性干扰lncRNA TRALR的表达可以阻滞胶质瘤细胞在G2/M期，抑制其增殖；促进SA‑β‑gal活性，促进胶质瘤细胞衰老；还能显著抑制BMI1、上调p21水平，促进细胞周期阻滞和衰老，增加脑胶质瘤替莫唑胺的敏感性。因此,可以将抑制lncRNA TRALR表达的试剂用于制备脑胶质瘤患者化疗增敏剂、治疗制剂。为脑胶质瘤患者的治疗提供强有力的分子生物学依据,具有深远的临床意义和重要的推广应用前景。
摘要（英）：

The invention discloses application of a preparation in inhibition of long-chain non-coding ribonucleic acid (lncRNA) TRALR. By means of the study of lncRNA sequencing, the lncRNA TRALR is found to behighly expressed in a temozolomide-resistant brain glioma cell line, and the specific interference of lncRNA TRALR expression can block brain glioma cells in a G2/M phase, so that the proliferation of the brain glioma cells is inhibited; the activity of SA-beta-gal is promoted, and the senescence of the glioma cells is accelerated; BMI1 is also significantly inhibited, the p21 level is up-regulated, cell cycle arrest and senescence are promoted, and the sensitivity of brain glioma temozolomide is improved. Therefore, a reagent for inhibiting the expression of the lncRNA TRALR can be used forpreparing a chemosensitizer and a treatment preparation for patients with the brain glioma. The application of the preparation in inhibition of the lncRNA TRALR provides a strong molecular biologicalbasis for the treatment of patients with the brain glioma, and has a far-reaching clinical significance and an important popularization and application prospect.

公开/授权文献
0/0